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Abstract
Hepatic stellate cells (HSCs), following transdifferentiation to myofibroblasts plays a key role in liver fibrosis. Therefore,
attempts to attenuate this myofibroblastic phenotype would be a promising therapeutic approach. Interferon gamma
(IFNc) is a potent anti-fibrotic cytokine, but its pleiotropic receptor expression leading to severe adverse effects has limited
its clinical application. Since, activated HSC express high-level of platelet derived growth factor beta receptor (PDGFbR), we
investigated the potential of PDGFbR-specific targeting of IFNc and its signaling peptide that lacks IFNcR binding site
(mimetic IFNc or mimIFNc) in liver fibrosis. We prepared DNA constructs expressing IFNc, mimIFNc or BiPPB (PDGFbR-
specific bicyclic peptide)-IFNc, BiPPB-mimIFNc fusion proteins. Both chimeric proteins alongwith IFNc and mimIFNc were
produced in E.coli. The expressed proteins were purified and analyzed for PDGFbR-specific binding and in vitro effects.
Subsequently, these recombinant proteins were investigated for the liver uptake (pSTAT1a signaling pathway), for anti-
fibrotic effects and adverse effects (platelet counts) in CCl4-induced liver fibrogenesis in mice. The purified HSC-targeted
IFNc and mimIFNc fusion proteins showed PDGFbR-specific binding and significantly reduced TGFb-induced collagen-I
expression in human HSC (LX2 cells), while mouse IFNc and mimIFNc did not show any effect. Conversely, mouse IFNc and
BiPPB-IFNc induced activation and dose-dependent nitric oxide release in mouse macrophages (express IFNcR while lack
PDGFbR), which was not observed with mimIFNc and BiPPB-mimIFNc, due to the lack of IFNcR binding sites. In vivo,
targeted BiPPB-IFNc and BiPPB-mimIFNc significantly activated intrahepatic IFNc-signaling pathway compared to IFNc and
mimIFNc suggesting increased liver accumulation. Furthermore, the targeted fusion proteins ameliorated liver fibrogenesis
in mice by significantly reducing collagen and a-SMA expression and potentiating collagen degradation. IFNc also induced
reduction in fibrogenesis but showed significant decrease in platelet counts, which was restored with targeted proteins.
These results suggest that these rationally designed proteins can be further developed as novel anti-fibrotic therapeutics.
Citation: Bansal R, Prakash J, De Ruiter M, Poelstra K (2014) Targeted Recombinant Fusion Proteins of IFNc and Mimetic IFNc with PDGFbR Bicyclic Peptide
Inhibits Liver Fibrogenesis In Vivo. PLoS ONE 9(2): e89878. doi:10.1371/journal.pone.0089878
Editor: Rafael Aldabe, Centro de Investigacio´n en Medicina Aplicada (CIMA), Spain
Received October 1, 2013; Accepted January 24, 2014; Published February 24, 2014
Copyright:  2014 Bansal et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Work was supported by VICI grant-in-aid from Netherlands Organization for Scientific Research (NWO; http://www.nwo.nl/) and the Technical
foundation (STW; http://www.stw.nl/). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: KP is scientific advisor and shareholder of BiOrion Technologies B.V., a company dedicated to the commercialization of drug carriers,
including the carrier presented here. This does not alter the authors’ adherence to all the PLOS ONE policies on sharing data and materials.
* E-mail: R.Bansal@utwente.nl
Introduction
IFNc is a pleiotropic homodimeric Th1 cytokine mainly
produced by activated inflammatory cells and has been docu-
mented to be highly effective in viral, immunological and
malignant diseases [1,2]. IFNc (Interferon gamma-1b) has also
been explored in clinical trials in patients suffering from liver
fibrosis, renal fibrosis or idiopathic pulmonary fibrosis [3–6].
However, despite its promising effects in vivo, all clinical trials failed
due to a lack of efficacy and unfavorable adverse effects [4,7,8].
The clinical application of this potent cytokine is nowadays limited
to only a very few diseases. Many attempts have been made to
prolong the half-life of IFNc by PEGylation or by increasing its
activity through slow release by incorporation in nanoparticles,
elastomers, microspheres or liposomes [9–11]. These approaches
have shown to be beneficial, but adverse effects due to the longer
exposure of IFNc to non-target tissues can still be detrimental.
Therefore, targeted approaches leading to an increased therapeu-
tic efficacy without eliciting adverse effects would be ideal to treat
slowly progressing chronic diseases [12].
Liver fibrosis, induced by viral infections (e.g hepatitis B and C),
alcohol abuse, metabolic syndrome or genetic disorders, is
characterized by an excessive accumulation of matrix proteins in
the liver [13,14]. Worldwide millions of people, suffering from one
of these disorders, are at risk of developing liver fibrosis. Currently,
there are no effective and clinically approved anti-fibrotic therapy
available and the treatment is mainly based on the removal of the
underlying cause of the disease [15,16]. Liver transplantation is the
only option for the patients suffering from advanced liver fibrosis
or end stage liver cirrhosis.
Hepatic stellate cells (HSC) are the key pathogenic cells involved
in the progression of liver fibrosis. These cells gets activated
following release of growth factors from damaged hepatocytes,
kupffer cells and infiltrating inflammatory cells. These activated
HSC are then transformed into proliferative and contractile
myofibroblast-like cells that produce large amounts of extracellular
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matrix (ECM) proteins leading to impairment of the structure and
function of liver [17,18]. Among the potent anti-fibrotic thera-
peutic cytokines, Interferon gamma (IFNc) is shown to be highly
efficacious in vitro and in vivo in liver fibrosis models [19], but it
failed in clinical trials due to reduced efficacy and unwanted
systemic effects [8].
Others and we have shown that activated HSC abundantly
express the platelet derived growth factor receptor (PDGFbR)
during liver fibrosis, while its expression is relatively weak on other
cells and normal tissues [20–22]. Recently, we have shown that
using PDGFbR-specific delivery of IFNc to activated HSC; acute
and advanced liver fibrosis in vivo could be significantly inhibited
with minimal adverse effects [20,23]. The results of these
chimerical constructs of IFNc and PDGFbR binding moieties
were remarkably potent and encouraged us to pursue this strategy
and prepare a targeted fusion proteins that are inexpensive and
can be feasibly applied in clinical trials.
To that end, we have now produced the recombinant proteins
containing a bicyclic PDGFbR-recognizing peptide (BiPPB) fused
to IFNc to synthesize BiPPB-IFNc or to the signaling moiety of
IFNc (mimetic IFNc or mimIFNc) lacking extracellular IFNcR
binding site [24,25] to generate BiPPB-mimIFNc in E.coli. IFNc
and mimetic IFNc were also expressed in parallel as control
proteins. These proteins were analyzed in vitro in human HSC cells
and in vivo in acute liver fibrogenesis mouse model. Encouragingly,
we found that the targeted fusion proteins (BiPPB-IFNc and
BiPPB-mimIFNc) specifically bound to PDGFbR-expressing
human HSC and induced significant reduction in major ECM
production in vitro (collagen). In vivo, in the CCl4 mouse model,
targeted proteins significantly stimulated the IFNc-mediated
pSTAT1a-signaling pathway, inhibited collagen accumulation,
HSC activation and induced fibrolysis. Apart from therapeutic
effects, BiPPB-mimIFNc and to a lesser extent BiPPB-IFNc did
not affect circulating platelets counts as observed by untargeted
IFNc.
Materials and Methods
Plasmids, Bacterial Strains and Cell Culture
pET42a and pET39b protein expression vectors were pur-
chased from Novagen (Madison, WI, USA). All the restriction
enzymes were procured from New England Biolabs (Beverly, MA).
Escherichia coli strain JM109 was used for plasmid propagation and
cloning. Strain BL21 (DE3) (Novagen) was used as a host for the
production of recombinant proteins. Human hepatic stellate cells,
LX2 were kindly provided by Prof. Scott Friedman (Mount Sinai
Hospital, New York). LX2 cell line is a well-established human
HSC cell line [26]. LX2 cells were cultured in DMEM-Glutamax
(Invitrogen, Carlsbad, CA) supplemented with 10% FBS and
antibiotics (50 U/ml penicillin and 50 ng/ml streptomycin).
Mouse spleen cells, freshly isolated from healthy C57BL/6 mice,
were grown in DMEM cell culture medium.
Plasmid Construction
(a) Preparation of pET42a-IFNc and pET42a-
mimIFNc. Splenocytes (freshly isolated from the spleen of
healthy C57BL/6 mice) were seeded in the presence of 20 mg/ml
phytohemagglutinin (PHA) for 24 h. RNA was isolated from
spleen cells was used for PCR amplification of mouse IFNc and
mimetic IFNc using gene specific primers (primer 1, primer 2 for
IFNc and primer 3, primer 4 for mimIFNc as listed in Table 1).
The PCR product was purified and digested with Eco RI. The
digested gene was inserted into Psh A1/Eco RI digested pET42a
vector to produce pET42a-IFNc or pET42a-mim IFNc (Figure
S1 and S2).
(b) Preparation of pET39b-BiPPB-IFNc and pET39b-
BiPPB-mimIFNc. For synthesis of pET39b-BiPPB-IFNc and
pET39b-BiPPB-mimIFNc, pET39b-BiPPB was prepared by PCR
extension of annealed primers (primer 5, primer 6 and primer 7,
primer 8 listed in Table 1). The resulting products (2 fragments)
were then digested with Bam HI and Not I, purified and ligated to
Sca I/Not I digested pET39b vector (Figure S3). Thereafter,
PCR amplified IFNc and mimIFNc (primer 9, primer 10 for IFNc
and primer 11, primer 12 for mimIFNc listed in Table 1) were
digested with Not I/Xho I and inserted into Not I/Xho I digested
and purified pET39b vector. The resulted recombinant vectors
were termed as pET39b-BiPPB-IFNc and pET39b-BiPPB-mi-
mIFNc that encodes for BiPPB and IFNc or mimIFNc plus a
three amino-acid linker (AAA) between them (Figure S4 and S5).
All the DNA constructs were confirmed by DNA sequencing.
pET42a-IFNc and pET42a-mimIFNc expressed proteins of 45.2 and
34.5 KDa respectively including GST tag, His tag, S tag and IFNc or
mimIFNc. pET39b-BiPPB-IFNc and pET39b-BiPPB-mimIFNc




Primer 1 TGCCACGGCCACAGTCATTGAAAGC –
Primer 2 GCGAATTCTCAGCAGCGACTCCTTTTC Eco RI
Primer 3 GCCAAGTTTGAGGTCAACAACCCACAG –
Primer 4 GCGAATTCTCAGCGACTCCTTTTCCG Eco RI
Primer 5 TGTTCTAGAAACCTCATCGATTGTAAG –
Primer 6 GCGGATCCCTTACAATCGATGAGGTT Bam HI
Primer 7 GCGGATCCGGAGGTTGTTCACGTAATCTAATAG Bam HI
Primer 8 TAGCGGCCGCTGAACAATCTATTAGATTA Not I
Primer 9 GGGCGGCCGCATGTCATGGTACAGTCATTGAA Not I
Primer 10 GCCTCGAGTTAGCAGCGACTCCTTTTCCG Xho I
Primer 11 AAGCGGCCGCAGCCAAGTTTGAGGTCAACAAC Not I
Primer 12 GCCTCGAGTTATCGACTCCTTTTCCGCTTCCTG Xho I
doi:10.1371/journal.pone.0089878.t001
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expressed 42.8 and 32.2 KDa fusion proteins respectively including
Dsb tag, His tag, BiPPB, linker and IFNc or mimIFNc.
Expression and Purification of Recombinant Proteins
DNA constructs were transformed into CaCl2 competent BL21
(DE3) and then induced with 1 mM IPTG at 37uC for 4 h.
For purification of IFNc and mimIFNc, the cell pellets were
washed and suspended in binding buffer (500 mM NaCl, 20 mM
sodium phosphate buffer, 20 mM Imidazole pH7.4), followed by
enzymatic lysis (0.2 mg/ml lysozyme, 20 mg/ml DNase, 10 mM
PMSF) for 30 min at 4uC and sonication for 10 min (10–15 short
bursts). The cell debris was removed by centrifugation at 12,000 g
for 30 min at 4uC. The supernatant was extensively dialyzed
against binding buffer.
For purification of periplasmic proteins BiPPB-IFNc and
BiPPB-mimIFNc, the cell pellets were suspended in 0.03 mol/l
Tris.HCl, 20% sucrose, 0.001 mol/l EDTA, pH8.0. The cells
were incubated on ice for 5–10 min followed by centrifugation at
8000 g for 20 min at 4uC. The pellet was then resuspended in ice-
cold 5 mM MgSO4 and stirred for 10 min on ice bath. The cell
debris was removed by centrifugation at 8000 g for 20 min at 4uC.
The supernatant was extensively dialyzed against binding buffer.
The supernatants were then applied to Ni-charged chelating-
Sepharose HisTrap High performance column (Pharmacia
Biotech, Uppsala, Sweden). After being washed with binding
Figure 1. Schematic representation of the prokaryotic vectors used for the expression of the recombinant proteins. IFNc (A) and
mimetic IFNc (B) were cloned in-frame upstream of His-tag in pET42a (+) vector to achieve cytoplasmic protein expression. The fusion proteins BiPPB-
IFNc (C) and BiPPB-mimIFNc (D) were expressed in pET39b (+) vector for periplasmic expression of fusion proteins to ensure proper folding and
disulfide bonds formation. For the synthesis of fusion proteins, BiPPB was fused to the N-terminal of IFNc or mimetic IFNc sequence through a flexible
3 amino acid linker (AAA) maintaining the open reading frame.
doi:10.1371/journal.pone.0089878.g001
Figure 2. Dot-blot and in vitro binding of recombinant proteins in human HSC. (A) Dot-blot analysis of purified recombinant proteins IFNc,
mimetic IFNc, BiPPB-IFNc and BiPPB-mimIFNc using anti-IFNc and anti-PPB antibody. (B) Representative pictures showing binding of BiPPB-IFNc and
BiPPB-mimIFNc to human HSC (LX2). Mouse IFNc and mimIFNc did not show any binding (similar to control) to human LX2 cells due to species
differences and lack of IFNcR or PDGFbR binding sites respectively.
doi:10.1371/journal.pone.0089878.g002
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buffer, the protein was eluted with the elution buffer containing
500 mM imidazole and then dialysed against PBS buffer
overnight.
Dot Blot Immunoassay
Purified proteins were applied on dehydrated PVDF membrane
(Roche, Mannheim, Germany) in dot-blot apparatus (Bio-Rad,
Hercules, CA, USA). The wells were then incubated with 200 ml
blocking solution (1% BSA in TBS) for 1 h. After washing in
TBST (0.05% tween 20 in TBS), the membrane was incubated for
1 h with either anti-IFNc antibody (1:2000; Abcam, Cambridge,
UK) or anti-PPB antibody (1:1000, custom-made, Harlan)
followed by 1 h incubation with horseradish peroxidase-labeled
secondary antibody. The membrane was washed again with TBST
subsequent with incubation in substrate solution (0.06% diamino-
benzidine (DAB), 0.08% hydrogen peroxide in TBS) for color
development. The membranes were finally rinsed in distilled water
and air-dried.
In vitro Binding of Recombinant Proteins in Human HSC
(LX2 Cells)
Cells (30,000 cells/well) were seeded in 24-well culture plates
(Becton Dickinson, Heidelberg, Germany) and grown overnight at
37uC/5%CO2. Then, cells were incubated with IFNc, mimIFNc,
BiPPB-IFNc or BiPPB-mimIFNc (1 mg/ml) for 2 h. Thereafter,
cells were fixed and stained using anti-PPB antibody.
In vitro Effects of Recombinant Proteins in Human HSC
Cells were plated in 24 well (30,000 cells/well) and 12 well
(75,000 cells/well) culture plates, grown overnight and were
starved with 0.5% containing medium for 24 h. Starved cells were
then incubated with medium alone, recombinant IFNc, mi-
mIFNc, BiPPB-IFNc or BiPPB-mimIFNc (equivalent to 1 mg/ml)
plus 5 ng/ml of human recombinant TGFb1 (Roche) for 48 h.
Subsequently, cells (24 well plates) were fixed and stained for
collagen I (1:100, Southern Biotech, Birmingham, AL). In
addition, cells (12 well plates) were lysed with 5x SDS-PAGE
sample buffer constituted with b-mercaptoethanol (Stratagene, La
Jolla, CA) to perform western blot analysis for collagen I (1:250;
Southern Biotech) and b-actin (house-keeping gene) as per
standard protocols.
Nitric Oxide (NO) Release Bioassay in Mouse RAW
Macrophages
The biological activity of recombinant proteins were assessed by
measuring the accumulation of nitrite NO2, a stable nitric oxide
Figure 3. In vitro effects of the recombinant proteins in human HSC and mouse macrophages. Representative pictures (A) and western
blot analysis (B) of collagen-I stained LX2 cells, incubated with TGFb (5 ng/ml) in combination with different recombinant proteins (1 mg/ml). In
human LX2 cells, only BiPPB-modified proteins attenuated collagen expression, whereas unmodified mouse IFNc and mimIFNc did not cause any
reduction due to species restriction and lack of receptor binding sites respectively. (C) Representative microscopic photographs depicting the
activation of mouse RAW macrophages after 24 h of incubation with mouse IFNc and BiPPB-IFNc (1 mg/ml) along with 100 ng/ml LPS. (D) Dose-
dependent release of nitrogen oxide (NOx) in mouse RAW macrophages after incubation with unmodified IFNc and BiPPB modified IFNc fusion
protein. MimIFNc and BiPPB-mimIFNc did not induce any NOx release due to absence of IFNcR binding site and/or lack of PDGFbR on RAW
macrophages.
doi:10.1371/journal.pone.0089878.g003
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(NO) metabolite produced by RAW macrophages as described
previously [27]. Briefly, cells (16105cells/200 ml/well) were seeded
in 96-well plates and grown overnight at 37uC/5%CO2. Then
cells were incubated with either medium alone or recombinant
proteins at different concentrations (10, 25, 50, 100 and 200 ng/
ml) together with 100 ng/ml lipopolysaccharides (LPS from E. coli
055:B5, Sigma). After 24 h, the secreted nitrite was measured
using Griess reagent (1% sulfanilamide; 0.1% naphthylethylendia-
mine dihydrochloride; 3% H3PO4). The absorbance was deter-
mined at 550 nm using an ELISA plate reader.
Animal Experiments: Ethics Statement
All the animal experiments were performed in strict accordance
with the guidelines and regulations for the Care and Use of
Laboratory Animals, University of Groningen, The Netherlands.
The protocols were approved by the Institutional Animal Ethics
Committee of the University of Groningen, The Netherlands
(Permit Number 5429A). Male 6- to 8-week old C57BL/6 mice
were purchased from Harlan (Zeist, Netherlands) and kept at 12 h
light/12 h dark cycles with ad libitum normal diet.
CCl4-induced Acute Liver Fibrogenesis Model in Mice
Acute liver injury was induced in male C57BL/6 mice by a
single intra-peritoneal injection of carbon tetrachloride (CCl4;
1 ml/kg prepared in olive oil) at day 1. At day 2 and day 3, mice
received intravenous injections of IFNc (n = 6), mimIFNc (n = 5),
BiPPB-IFNc (n = 6), BiPPB-mimIFNc (n = 6) (equivalent to 5 mg
IFNc/mouse/day) or PBS alone. At day 4, all mice were sacrificed
under deep anesthesia by cervical dislocation; blood and livers
were collected for subsequent measurements.
In vivo IFNc (pSTAT1a) Signaling Pathway
The IFNc signaling pathway was analyzed in the acute liver
fibrogenesis model in mice after 24 h of administration with IFNc
(n = 6), mimIFNc (n = 5), BiPPB-IFNc (n = 6), BiPPB-mimIFNc
(n = 6) (equivalent to 5 mg IFNc/mouse/day) or PBS alone. Liver
tissues samples were homogenized in cold RIPA buffer (50 mM
Tris-HCl, 150 mM NaCl, 0.1% SDS, 0.1% Igepal in 0.5%
sodium deoxycholate, 1 tablet of protease inhibitor cocktail and 1
tablet of phosphatase inhibitor in 10 ml) on ice using a tissue
homogenizer and the lysates were centrifuged at 12,000 rpm for
1 h at 4uC. 20 mg of protein was used for western blot analysis
performed as per standard protocols using anti-pSTAT1a
antibody (1:1000; cell signaling, Beverly, MA) or anti-b-actin
antibody (1:5000; Sigma).
Immunohistochemistry and Immunofluorescence
The cells were fixed with acetone:methanol (1:1), dried and
stored until immunostaining. Livers were harvested and trans-
ferred to Tissue-Tek OCT embedding medium, and snap frozen
in isopentane chilled in a dry ice. Cryosections (4 mm) were cut
using a Leica CM 3050 cryostat (Leica Microsystems, Nussloch,
Germany). The sections were allowed to adhere to Superfrost
microscopic glass slides (Menzel-Gla¨ser, Braunschweig, Germany),
air-dried and fixed with acetone for 10 min. Cells or tissue sections
were rehydrated with PBS and incubated with the collagen I
antibody (1:100; Southern Biotech), a-SMA antibody (1:600,
Sigma) or PPB (1:100; custom-made, Harlan) for 1 h. Thereafter,
cells or sections were washed thrice with PBS and incubated with
horseradish peroxidase (HRP)-conjugated secondary antibody for
30 min. Cells or sections were washed again and further incubated
with HRP-conjugated tertiary antibody for 30 min. Thereafter,
peroxidase activity was developed with 3-amino-9-ethyl carbazole
(Sigma, St. Louis,MO) for 20 min and nuclei were counterstained
with hematoxylin (Fluka Chemie, Buchs, Switzerland). Cells or
sections were then mounted with Kaiser’s gelatin (Darmstadt,
Germany), visualized and photographed using a light microscope
(Olympus UK Ltd., Essex, UK).
Quantitative Real-time PCR
Total RNA from liver tissues was isolated using RNeasy mini kit
(Qiagen, Hilden, Germany) according to manufacturer’s instruc-
tions. RNA concentrations were quantitated by a Nanodrop UV
spectrophotometer (NanoDrop Technologies, Wilmington, DE).
Total RNA (1.6 mg) was reverse transcribed in a volume of 50 ml
using cDNA synthesis kit (Promega, Madison, WI). All primers
were purchased from Sigma-Genosys (Haverhill, UK). Following
primers were used, MMP13 forward: CCAGAACTTCCCAAC-
CATGT; MMP13 reverse: GTCTTCCCCGTGTTCTCAAA;
TIMP1 forward: ATCAGTGCCTGCAGCTTCTT; TIMP1
reverse: TGACGGCTCTGGTAGTCCTC; GAPDH forward:
ACAGTCCATGCCATCACTGC; GAPDH reverse: GATC-
CACGACGGACACATTG. The reactions were performed with
20 ng cDNA using SYBR green PCR master mix (Applied
Biosystems, Foster City, CA) according to manufacturer’s instruc-
tions and were analyzed by ABI7900HT sequence detection
system (Applied Biosystems). Finally, the threshold cycles (Ct) were
calculated and relative gene expression was normalized with
GAPDH (for mouse) as housekeeping gene.
Figure 4. In vivo activation of IFNc pSTAT1a signaling pathway
by recombinant proteins. Western blot analysis of pSTAT1a after
24 h post intravenous administration of IFNc (n = 6), MimIFNc (n = 5),
BiPPB-IFNc (n = 6), BiPPB-mimIFNc (n = 6) or PBS alone (n = 6). The graph
shows significant increase in activation of pSTAT1a with HSC-targeted
fusion proteins (BiPPB-IFNc, BiPPB-mimIFNc). Bars represent mean 6
SEM of 5–6 mice per group. *P,0.05 and **P,0.01 versus PBS treated
CCl4 mice. The groups were normalized to CCl4 group (treated with
PBS).
doi:10.1371/journal.pone.0089878.g004
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Statistical Analyses
Data are presented as mean 6 standard error mean (SEM).
Multiple comparisons between different groups were performed by
one-way ANOVA with Bonferroni post-test using GraphPad
Prism version 5.02 (GraphPad Prism Software, Inc., La Jolla, CA,
USA).
Results
Construction and Expression of Recombinant Proteins
We synthesized four recombinant proteins: IFNc, mimetic IFNc
(mimIFNc), BiPPB-IFNc and BiPPB-mimetic IFNc (BiPPB-
mimIFNc) (Figure 1). IFNc and mimetic IFNc were expressed
using pET42a derived bacterial expression vector to achieve
cytoplasmic expression of the proteins (Figure 1A, 1B and
Figure S1, S2). While, BiPPB-IFNc and BiPPB-mimIFNc fusion
proteins were expressed using pET39b (+) expression vector
(Figure 1C, 1D and Figure S4, S5) to yield periplasmic
expression, required for their proper folding. DNA constructs were
extensively analysed for the presence of inserts using specific
restriction enzyme digestions and by automated DNA sequencing.
Thereafter, constructs were transformed into E. coli strain BL21
(DE3) and protein expression was induced by 1 mM IPTG.
Proteins of interest with the expected molecular weight were found
in total cell pellets. Soluble proteins were purified from the
supernatant of lysed bacterial pellets through Ni-NTA affinity
columns. Purified proteins were further dialysed against PBS and
concentrated by ultrafiltration. The presence of IFNc moieties or/
and PPB peptides in the prepared fusion proteins was confirmed in
dot blots using anti-IFNc and anti-PPB antibodies (Figure 2A).
In vitro Binding of Recombinant Proteins in Human HSC
The binding of IFNc to its receptor is strictly species-specific,
whereas PDGFbR binding is not. In order to demonstrate
PDGFbR-specific binding of BiPPB containing fusion proteins,
we used human LX2 hepatic stellate cells that are known to
express PDGFbR. The results confirmed the species specificity of
IFNc; mouse IFNc and mimetic IFNc (lacking extracellular
IFNcR binding site) did not show any binding to human HSC
(Figure 2B). However, BiPPB-fused mouse IFNc or mimetic
IFNc proteins showed high binding to human cells (Figure 2B).
In vitro Effects of Recombinant Proteins in Human HSC
and Mouse Macrophages
Following the binding studies, we investigated the anti-fibrotic
effects of the recombinant proteins in human HSC after their
activation with TGFb. In corroboration with the binding studies in
human LX2 cells, TGFb-induced collagen expression was strongly
inhibited by treatment with the PDGFR-specific BiPPB-IFNc and
Figure 5. Effects of recombinant proteins on fibrotic parameters in vivo. (A) Representative pictures of collagen I and a-SMA stained liver
sections from olive oil treated mice (normal) or CCl4-treated mice (acute model) that were treated with IFNc (n = 6), MimIFNc (n = 5), BiPPB-IFNc
(n = 6), BiPPB-mimIFNc (n = 6) or PBS alone (n = 6). Scale bars, 200 mm. (B) Whole-liver lysates from treated animals were subjected to western blot
analysis using anti-collagen I antibody. Graph represents collagen I expression (normalized with b-actin) depicted as mean 6 SEM from n= 5–6 mice
per group.#P,0.05 denotes significance versus PBS treated olive oil mice and *P,0.05, **P,0.01 denotes significance versus PBS treated-CCl4 mice.
For quantitative analysis, the groups were normalized to vehicle group (PBS treated-CCl4 mice). (C) Effect of recombinant proteins on intrahepatic
fibrinolysis as determined by the ratio of MMP13 and TIMP-1 transcripts. The groups were normalized to vehicle group (PBS treated-CCl4 mice). Bars
represent mean 6 SEM of 5–6 mice per group. *P,0.05, **P,0.01 denotes significance versus PBS treated-CCl4 mice.
doi:10.1371/journal.pone.0089878.g005
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-mimIFNc fusion proteins (Figure 3A, 3B) as analyzed by
immunostaining and western blot analysis. While both mouse
IFNc and mimIFNc did not induce any effect in human cells due
to species differences and the absence of a receptor-binding site
respectively. On the other hand, mouse IFNc and BiPPB-IFNc
strongly potentiated LPS-induced activation and dose-dependent
release of nitric oxide in mouse RAW macrophages due to
presence of mouse IFNcR (Figure 3C, 3D). However, mimIFNc
lacking the IFNcR binding site and mimIFNc-BiPPB directed to
PDGFbR did not induce any effect due to lack of PDGFbR
expression on macrophages (Figure 3C, 3D).
In vivo Liver Uptake of BiPPB-modified Fusion Proteins in
Acute CCl4-induced Liver Fibrosis in Mice
Others and we have earlier demonstrated that PDGFbR is
highly upregulated on activated HSC during acute and advanced
liver fibrosis [20,21]. Our group has extensively studied the bio-
distribution of proteins modified with PDGFbR-recognizing cyclic
peptides (PPB), using radiolabeled and imaging studies, and
showed high distribution of PPB-modified proteins to PDGFbR-
expressing hepatic stellate cells in fibrotic livers [23]. In the present
study, we assessed the intracellular activation of the pSTAT1a
signaling pathway after 24 h of IFNc, mimIFNc, BiPPB-IFNc and
BiPPB-mimIFNc administration in CCl4-induced liver fibrosis in
mice. We found a significant increase in pSTAT1a activation after
24 h of treatment with BiPPB-IFNc (p,0.05) and BiPPB-
mimIFNc (p,0.01) compared to PBS, IFNc and mimIFNc
treatments indicating enhanced liver uptake of the fusion proteins
due to high PDGFbR expression on activated HSC in the fibrotic
livers (Figure 4 and Figure S6).
In vivo Effects of BiPPB-modified Fusion Proteins in Acute
CCl4-induced Liver Fibrosis Model in Mice
A single CCl4 administration induced acute liver injury in mice,
characterized by an increased intrahepatic expression of HSC
activation marker (a-smooth muscle actin) and an increased
deposition of extracellular matrix molecule (collagen I) as shown in
Figure 5A–5C. IFNc, mimIFNc, BiPPB-IFNc and BiPPB-
mimIFNc proteins were examined for their anti-fibrotic effects
in this experimental model in mice. After two intravenous
injections, a strong reduction in collagen I expression was observed
with IFNc (<45% reduction, p,0.05), HSC-targeted BiPPB-IFNc
(<50% reduction, p,0.05) and BiPPB-mimIFNc (<60% reduc-
tion, p,0.01) as analyzed by immunostaining and quantitative
western blot analysis (Figure 5A, 5B and Figure S7).
Furthermore, a-SMA expression was attenuated by HSC-targeted
BiPPB-IFNc administration and more strongly by BiPPB-
mimIFNc treatment as shown in Figure 5A, while IFNc had
only little effect and mimIFNc did not induce any reduction in a-
SMA expression levels (Figure 5A). Apart from collagen
expression and deposition, the balance between collagen degrad-
ing matrix metalloproteinases-13 (MMP-13) and their major
endogenous inhibitor, tissue inhibitor of metalloproteinases-1
(TIMP-1), is an important determinant of progression or reversal
of fibrosis [28,29]. A significant increase in MMP13/TIMP1
transcript ratio was observed after treatment with IFNc (p,0.05),
BiPPB-IFNc (p,0.01) and BiPPB-mimIFNc (p,0.01) suggesting
activation of fibrolysis and induction of reversal of fibrosis
(Figure 5C). Of note, no effect was observed with mimetic IFNc
alone due to lack of an IFNcR binding site while the inhibitory
effects of HSC-targeted BiPPB-modified fusion proteins on
collagen deposition were higher compared to non-targeted IFNc
(Figure 5).
The main hurdles in IFNc-based therapies are the adverse
effects that led to the failure of clinical trials. IFN-mediated
reduction in blood platelets is clinically relevant and a well-known
side effect [30]. Indeed, we observed a significant reduction in the
platelet counts following two intravenous treatments with IFNc
(p,0.001), which was significantly improved following treatment
with BiPPB-mimIFNc and to a lesser extent with BiPPB-IFNc
(Figure 6). MimIFNc did not induce a significant change in
platelets counts due to lack of binding to IFNcR or PDGFbR.
Discussion
Hepatocellular damage, hepatic inflammatory cell infiltration
and extensive tissue remodeling ultimately culminate into the
development of progressive fibrosis and cirrhosis [31]. During liver
fibrosis, the interplay between growth factors and cytokines
produced by the damaged hepatocytes; inflammatory cells and
non-parenchymal cells activate quiescent hepatic stellate cells
(HSC). These activated HSC in turn proliferate and accumulate in
the injured liver producing large amounts of extracellular matrix
proteins [32]. Therefore, therapeutic approaches to silence these
activated HSC would be appropriate to inhibit or reverse liver
fibrosis [12].
Fibrosis is an heterogeneous process e.g. CCl4 intoxication
results in hepatocyte damage, necrosis, inflammation, and fibrosis,
Figure 6. Effects of recombinant proteins on IFNc-related
adverse effect in the acute CCl4 model. Graph represents platelet
counts measured in CCl4-treated mice receiving PBS (n = 6) or the
different recombinant proteins IFNc (n = 6), MimIFNc (n = 5), BiPPB-IFNc
(n = 6), BiPPB-mimIFNc (n = 6). Bars represent mean 6 SEM of 5–6 mice
per group. The results showed a significant reduction in platelet counts
following two intravenous administration of IFNc, which was signifi-
cantly improved following treatment with BiPPB-mimIFNc and to a
lesser extent with BiPPB-IFNc. MimIFNc did not show significant change
in platelets counts due to lack of binding to IFNcR or PDGFbR. *P,0.05,
**P,0.01 denotes significance versus PBS treated CCl4 mice. #P,0.05
denotes the significance versus IFNc-treated CCl4 mice.
doi:10.1371/journal.pone.0089878.g006
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leading to portal fibrosis or cirrhosis. While bile duct ligation
(BDL) stimulates the proliferation of biliary epithelial cells and oval
cells, resulting in proliferating bile ductules accompanied by portal
inflammation leading to biliary cirrhosis (PBC). As documented in
fibrotic animal models (BDL or CCL4 etc.) and diseased human
livers, PDGFbR is expressed abundantly on activated HSC or
portal fibroblasts (collectively referred as myofibroblasts-like cells)
[21,22]. The expression was found to be very weak in normal
healthy tissues or cells (pericytes or smooth muscle cells) relative to
expression levels in the fibrotic livers, which motivated us to
examine the potential of using PDGFbR for a targeted delivery of
anti-fibrotic or apoptotic drugs to the fibrotic livers [12]. In the
present study, we have directed IFNc or mimetic IFNc (signaling
moiety of IFNc lacking extracellular IFNcR binding site while
retaining activities of IFNc) [33] to PDGFbR-expressing activated
HSC using bicyclic PDGFbR peptides to inhibit liver fibrosis with
reduced adverse effects.
IFNc or mimetic IFNc modified with bicyclic PDGFbR-
recognizing peptide were generated via recombinant technology
in E.coli. Unmodified IFNc or mimetic IFNc were also produced
in parallel to serve as respective controls. BiPPB-IFNc and BiPPB-
mimIFNc were produced from a periplasmic vector (pET39b),
since this vector contains the DsbA tag that exports the expressed
proteins to the periplasmic space (space between plasma mem-
brane and outer membrane). DsbA, periplasmic enzyme catalyzes
the sequential formation of disulfide bonds therefore favors proper
folding of the fusion proteins containing bicyclic peptide (cyclized
via bisulfide bonds) at the N-terminus of IFNc and mimetic IFNc.
Unmodified IFNc and mimetic IFNc were produced using
pET42a vector as cytoplasmic proteins. These proteins were
expressed, purified and analyzed using immune dot-blots where
the presence of IFNc, mimIFNc, BiPPB-IFNc and BiPPB-
mimIFNc was confirmed using anti-IFNc and anti-PPB antibod-
ies.
The BiPPB-modified proteins were investigated for PDGFbR-
specific binding in human HSC. BiPPB-IFNc and BiPPB-
mimIFNc showed specific binding to PDGFbR-expressing human
LX2 cells whereas unmodified mouse derived IFNc and mimIFNc
did not show binding to these human cells due to species restrictive
interaction of mouse IFNc to mouse IFNcR, while PDGFbR
interaction is not species-specific. BiPPB-IFNc and BiPPB-
mimIFNc also induced a strong reduction in TGFb-induced
collagen I expression in human LX2 cells while IFNc and
mimIFNc did not affect the collagen expression in these cells
corroborating with the binding studies. We did not observe any
difference in a-SMA expression in vitro after 48 hrs of treatment
(data not shown) while significant reduction is observed in collagen
expression (Figure 3A, 3B), since IFNc has shown to have direct
effect on collagen expression by directly acting on C/EBPbeta
signaling pathway [34] while longer treatments might lead to
inhibitory effects on a-SMA expression. These studies clearly
demonstrate that directing IFNc or mimetic IFNc to the accessory
PDGFbR can transform mouse (whose activity is restricted to
mouse cells) and mim-IFNc (unable to enter any cell), into highly
active proteins in human LX2 cells. On the other hand, we studied
effect of these recombinant proteins in mouse macrophages
expressing IFNcR and lacking PDGFbR. Results showed that
IFNc or BiPPB-modified IFNc containing IFNcR binding site
activated mouse RAW cells and induced NO release while both
mimIFNc (lacking IFNcR binding site) or BiPPB-modified
mimIFNc (containing PDGFbR binding site and lacking IFNcR
binding site) did not show any effect in macrophages. These results
indicate that targeted mimIFNc will not influence cell types
(especially macrophages which are known to be highly influenced
by IFNc) other than PDGFbR-expressing cells and therefore will
not induce adverse effects in other normal cells or tissues.
In the past years, our group has extensively demonstrated the
higher liver accumulation and HSC-specific distribution of PPB-
modified proteins [35]. Here we examined the intra-hepatic
activation of IFNc signaling pathway in vivo in treated livers to
assess the increased accumulation of our targeted proteins in
fibrotic livers. IFNc internalization results in the activation of the
JAK–STAT pathway and subsequent phosphorylation of signal
transducers and activators of transcription (STAT1) that binds to
unique gamma-activated sequence (GAS) regulating IFNc-respon-
sive genes [36]. Both BiPPB-modified IFNc and mimIFNc
induced a significant increase in intrahepatic pSTAT1a signalling
compared to unmodified IFNc and mimiFNc implicating
increased liver accumulation of targeted proteins.
Thereafter, we studied the anti-fibrotic effects of recombinant
proteins in the CCl4-induced liver fibrogenesis model in mice. This
model is associated with HSC activation, enhanced PDGFR
expression and ECM deposition, the key parameters of fibrogen-
esis. Two subsequent intravenous injections of IFNc, BiPPB-IFNc
or BiPPB-mimIFNc led to the highly significant reduction in
collagen I expression (major extracellular matrix protein) and a-
SMA (HSC activation marker) expression. Additionally, IFNc,
BiPPB-IFNc and BiPPB-mimIFNc enhanced the MMP13/
TIMP1 transcripts ratio implying activation of fibrolysis. In this
study, we observed anti-fibrotic effects with IFNc in comparison
with our previously reported studies [20,23], is attributed to the
increased dose (5 mg) used here, as compared to 2.5 mg dose used
earlier. MimIFNc that cannot be internalized due to lack of
receptor binding sites did not show any effect on these fibrotic
PPB-modified proteins can block the PDGFbR in vitro [35,37]
and this might also account for the observed antifibrotic effects.
However, previous studies with PPB-peptides coupled to albumin
have shown that this effect does not occur in vivo at the doses used
[20,23]. To further reinforce this hypothesis, we used synthetic
BiPPB as a control but did not observed any effect on the fibrotic
parameters (data not shown).
Liver fibrosis or cirrhosis is a slowly progressing disease that
develops over many years, therefore patients are treated for longer
periods to cure or reverse the disease. Therefore, therapies with
improved therapeutic efficacy and preferably without provoking
off-target systemic effects would be highly favourable. In clinical
trials with IFNc, patients suffered from mild to severe adverse
effects; therefore we investigated one of the well-known IFN-
mediated adverse effects, significant reduction in circulating blood
platelets (mainly produced by bone marrow) can lead to fatal
disorders and also found to be associated with the serotonin levels
associated to depression [30]. We found that only two intravenous
injections of IFNc led to a highly significant reduction in platelet
counts (p,0.001) in comparison to PBS-treated mice. Further-
more, BiPPB-IFNc that can still interact with IFNcR receptor
showed a slight reduction in platelet counts (p,0.05), but
mimIFNc (without receptor binding sites) and BiPPB-mimIFNc
(only specific to PDGFbR) did not induce a reduction in platelet
counts. Further studies in long-term fibrotic models are important
to examine the adverse effects of targeted constructs due to the
long-term administration. Since platelets are produced by bone
marrow, it is also important to study the effect of these constructs
on the bone marrow as these effects may influence other crucial
biological processes.
In conclusion, the results in this paper clearly demonstrate that
HSC-targeted mimIFNc is capable of accumulating in PDGFbR-
expressing fibrotic livers and exerting an inhibitory effect on
fibrotic parameters, which makes this recombinant protein a
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highly attractive candidate to explore for the treatment of liver
fibrosis. The recombinant synthesis of this chimeric compound will
facilitate further translational research with this compound.
Supporting Information
Figure S1 Schematic representation depicting cloning
strategy for preparation of pET42a-IFNc. PCR amplified
and EcoRI digested mouse IFNc gene fragment was cloned in
pET42a (+) prokaryotic vector at Psh A1/Eco RI site.
(TIF)
Figure S2 Schematic representation depicting cloning
strategy for preparation of pET42a-mimIFNc. PCR
amplified and EcoRI digested mouse mimetic IFNc gene fragment
was cloned in pET42a (+) prokaryotic vector at Psh A1/Eco RI
site.
(TIF)
Figure S3 Schematic representation depicting cloning
strategy for preparation of pET39b-BiPPB. BiPPB was
prepared by annealing and PCR extension of 2 sets of primers
(refer to methods), which were linked together via Bam HI site and
cloned in Sca I/Not I digested pET39b (+) prokaryotic vector.
(TIF)
Figure S4 Schematic representation depicting cloning
strategy for preparation of pET39b-BiPPB-IFNc. PCR
amplified IFNc prepared for fusion with BiPPB was digested with
Not I/Xho I was cloned in pET39b vector at Not I/Xho I site.
The resultant recombinant vector termed as pET39b-BiPPB-IFNc
encodes for BiPPB and IFNc plus a three amino-acid linker (AAA)
between them.
(TIF)
Figure S5 Schematic representation depicting cloning
strategy for preparation of pET39b-BiPPB-mimIFNc.
PCR amplified mimIFNc prepared for fusion with BiPPB was
digested with Not I/Xho I was cloned in pET39b vector at Not I/
Xho I site. The resultant recombinant vector termed as pET39b-
BiPPB-mimIFNc encodes for BiPPB and mimIFNc plus a three
amino-acid linker (AAA) between them.
(TIF)
Figure S6 In vivo activation of IFNc pSTAT1a signaling
pathway by recombinant proteins. Representative western
blot images of pSTAT1a (upper panel) and b-actin (house-keeping
protein, lower panel) after 24 h post intravenous administration of
IFNc (n = 6), MimIFNc (n = 5), BiPPB-IFNc (n = 6), BiPPB-
mimIFNc (n = 6) or PBS alone (n= 6). Figure shows the significant
increase in activation of pSTAT1a with HSC-targeted fusion
proteins (BiPPB-IFNc, BiPPB-mimIFNc).
(TIF)
Figure S7 Effects of recombinant proteins on fibrotic
parameters in vivo. Representative western blot images of
collagen I (upper panel) and b-actin (house-keeping protein, lower
panel) from CCl4-treated mice (acute model) that were treated
with IFNc (n = 6), MimIFNc (n = 5), BiPPB-IFNc (n = 6), BiPPB-
mimIFNc (n = 6) or PBS alone (n= 6). Figure shows the significant
reduction in collagen expression after treatment with HSC-
targeted fusion proteins (BiPPB-IFNc, BiPPB-mimIFNc).
(TIF)
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